The clinical spectrum of muscle- and skeletal-related side-effects of statins includes varied myalgias and weakness, an asymptomatic increase in the concentration of creatine kinase and other biochemical parameters, myositis and rhabdomyolysis. Currently, there is no consensus on the definition of ‘statin myopathy’. Evidence suggests that deleterious effects may also be associated with the volume or dosage of structured exercise and/or the intensity of physical activity. Moreover, non-muscle adverse effects on the joints and tendons are often overlooked and underemphasized. The incidence of myopathy associated with statin treatment typically ranges between 1.5% and 10%. Few data are available regarding the prevalence of muscle- related symptoms associated with different statins and the distribution of affected muscles. Furthermore, discrepancies between clinical trials and daily practice may emanate, in part, because of inconsistent definitions or exclusion criteria.
The pathophysiology of statin-related myopathy is incompletely understood. A dose-dependent and proapoptotic effect, direct effects on mitochondria, drug interactions and genetic factors, or combinations thereof, may be involved. Recently, a rare immune-mediated myopathy triggered by statin use has been described. With the increasing number of patients treated with statins and with more patients being prescribed high doses of potent statins to achieve low-density lipoprotein targets, muscle-related side-effects will become more prevalent. Currently, the only effective treatment is the discontinuation of statin use. Further research is needed to develop alternative LDL-lowering drugs when statins are not well tolerated and to establish additional effective strategies to manage lipids and lipoproteins.
PerkJDe BackerGGohlkeH. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J2012; 33: 1635–1701.
2.
ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J2011; 32: 1769–1818.
3.
ZhouQLiaoJk. Pleiotropic effects of statins – basic research and clinical perspectives. Circ J2010; 74: 818–826.
4.
ThompsonPDGadaletaPAYurgalevitchS. Effects of exercise and lovastatin on serum creatine kinase activity. Metabolism1991; 40: 1333–1336.
5.
StaffaJAChangJGreenL. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med2002; 346: 539–540.
6.
GolombBAEvansMA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs2008; 8: 373–418.
7.
McKenneyJMDavidsonMHJacobsonTA. National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol2006; 97: 89C–94C.
8.
SinzingerHSchmidPO’GradyJ. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. Atherosclerosis1999; 143: 459–460.
9.
PhillipsPSHaasRHBannykhS. Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med2002; 137: 581–585.
10.
PasternakRCSmithSCJrBairey-MerzCN. American College of Cardiology. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation2002; 106: 1024–1028.
BruckertEHayemGDejagerS. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther2005; 19: 403–414.
13.
MarieIDelafenetreHMassyN. and the network of the French Pharmacovigilance Centers. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990–2005 and review of the literature. Arthritis Rheum2008; 59: 367–372.
14.
CrouseJRIIIRaichlenJSRileyWA. for the METEOR Study Group. Effect of Rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR Trial. JAMA2007; 297: 1344–1353.
15.
MovahedMRSamsamsharaiatSA. Reproducible tendinitis-like symptoms related to statin therapy. J Clin Rheumatol2006; 12: 320–321.
16.
ChazerainPHayemGHamzaS. Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine2001; 68: 430–433.
17.
HoffmanKBKrausCDimbilM. A survey of the FDA’s AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One2012; 7: e42866–e42866. doi:10.1371/journal.pone.0042866.
18.
MansiIFreiCRPughMJ. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med2013; 173: 1–10.
19.
BakerJFWalshPMulhallKJ. Statins: a potential role in the management of osteoarthritis?Joint Bone Spine2011; 78: 31–34.
20.
BuettnerCRippbergerMJSmithJK. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med2012; 125: 176–182.
21.
BuettnerCDavisRBLeveilleSG. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med2008; 23: 1182–1186.
22.
MampuyaWFridDRoccoM. Treatment stategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J2013; 166: 597–603.
23.
KashaniAPhillipsCOFoodyJM. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation2006; 114: 2788–2797.
24.
KjekshusJApetreiEBarriosV. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med2007; 357: 2248–2261.
25.
TavazziLMaggioniAPMarchioliR. Gissi-HF Investigators. Effect of rosuvastatin in patients with heart failure. Lancet2008; 372: 1231–1239.
26.
BaigentCLandrayMJReithC. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet2011; 377: 2181–2192.
27.
NoharaRDaidaHHataM. Justification for Atherosclerosis Regression Treatment (JART) Investigators. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study. Circ J2012; 76: 221–229.
28.
CollinsGSAltmanDG. Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK. Heart2012; 98: 1091–1097.
29.
ArmitageJBowmanLWallendszusK. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Lancet2010; 376: 1658–1669.
30.
YamazakiTNoharaRDaidaH. Justification for Atherosclerosis Regression Treatment (JART) Investigators. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. Int Heart J2013; 54: 33–39.
31.
SinzingerHWolframRPeskarBA. Muscular side effects of statins. J Cardiovasc Pharmacol2002; 40: 163–171.
32.
MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet2002; 360: 7–22.
33.
DownsJRClearfieldMWeisS. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998; 279: 1615–1622.
34.
PfefferMAKeechASacksFM. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation2002; 105: 2341–2346.
35.
NewmanCBPalmerGSilbershatzH. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol2003; 92: 670–676.
36.
MohlerER3rdHiattWRCreagerMA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation2003; 108: 1481–1486.
37.
HoldaasHFellströmBJardineAG. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet2003; 361: 2024–2031.
NewmanCBSzarekMColhounHMBetteridgeDJDurringtonPNHitmanGANeilHADemiccoDAAusterSFullerJH. Cards Investigators. The safety and tolerability of atorvastatin 10 mg in the collaborative atorvastatin diabetes study (CARDS). Diab Vasc Dis Res2008; 5: 177–183.
40.
LaRosaJCGrundySMWatersDD. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med2005; 7: 1425–1435.
41.
NicholsGAKoroCE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32225 diabetic and nondiabetic patients. Clin Ther2007; 29: 1761–1770.
42.
El-SalemKAbabnehBRudnickiS. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve2011; 44: 877–881.
43.
MosshammerDLorenzGMeznaricS. Statin use and its association with musculoskeletal symptoms: a cross-sectional study in primary are settings. Fam Pract2009; 26: 88–95.
44.
MolokhiaMMcKeiguePCurcinV. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006. PLoS One2008; 3: e2522–e2522.
45.
VandenbergBFRobinsonJ. Management of the patient with statin intolerance. Curr Atheroscler Rep2010; 12: 48–57.
46.
MRC/BHF Heart Protection Study Collaborative GroupEffects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20536 high-risk people. In: ArmitageJBowmanLCollinsR (eds). BMC Clin Pharmacol2009; 9: 6–6.
47.
NewmanCTsaiJSzarekM. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14 236 patients. Am J Cardiol2006; 97: 61–67.
48.
GrahamDJStaffaJAShatinD. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA2004; 292: 2585–2590.
49.
GuytonJR. Benefit versus risk in statin treatment. Am J Cardiol2006; 97: 95C–97C.
50.
MillsEJWuPChongG. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM2011; 104: 109–124.
51.
de LemosJABlazingMAWiviottSD. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA2004; 292: 1307–1316.
52.
LawMRudnickaAR. Statin safety: a systematic review. Am J Cardiol2006; 97: 52C–60C.
53.
ChangJTStaffaJAParksM. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf2004; 13: 417–426.
54.
SilvaMASwansonACGandhiPJ. Statin-related adverse events: a meta-analysis. Clin Ther2006; 28: 26–35.
55.
OshimaY. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med2011; 50: 845–853.
56.
HolbrookAWrightMSungM. Statin-associated rhabdomyolysis: is there a dose-response relationship?Can J Cardiol2011; 27: 146–151.
57.
ArmitageJ. The safety of statins in clinical practice. Lancet2007; 370: 1781–1790.
58.
ThompsonPDClarksonPMRosensonRS. An assessment of statin safety by muscle experts. Am J Cardiol2006; 97: 69C–76C.
59.
SettergrenJEiermannBMannheimerB. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy – a nationwide register study. PLoS One2013; 8: e69545–e69545.
60.
RallidisLSFountoulakiKAnastasiou-NanaM. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol2012; 159: 169–176.
61.
HansenKEHildebrandJPFergusonEE. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med2005; 165: 2671–2676.
62.
MolokhiaMMcKeiguePCurcinV. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006. PLoS One2008; 3: e2522–e2522.
63.
MammenALAmatoAA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol2010; 22: 644–650.
64.
AldaoAMenninDSLinardatosE. Differential patterns of physical symptoms and subjective processes in generalized anxiety disorder and unipolar depression. J Anxiety Disord2010; 24: 250–259.
65.
VaccarinoALSillsTLEvansKR. Multiple pain complaints in patients with major depressive disorder. Psychosom Med2009; 71: 159–162.
66.
KavanMGElsasserGNBaroneEJ. Generalized anxiety disorder: practical assessment and management. Am Fam Physician2009; 79: 785–791.
67.
KlugeMDittmanRWLehmannM. Muscular complaints and headache are common painful physical symptoms in patients with depression. Ger J Psychiatry2006; 9: 101–106.
68.
AndradeC. Selective serotonin reuptake inhibitor drug interactions in patients receiving statins. J Clin Psychiatry2014; 75: e95–e99.
69.
WestwoodFRBigleyARandallK. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol2005; 33: 246–257.
70.
YangCHoelzleMDisanzaA. Coordination of membrane and actin cytoskeleton dynamics during filopodia protrusion. PLoS One2009; 4: e5678–e5678.
71.
RosensonRS. Current overview of statin-induced myopathy. Am J Med2004; 116: 408–416.
72.
BakerSK. Molecular clues into the pathogenesis of statin mediated muscle toxicity. Muscle Nerve2005; 31: 572–580.
73.
PäiväHThelenKMVan CosterR. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther2005; 78: 60–68.
74.
La GuardiaPGAlbericiLCRavagnaniFG. Protection of rat skeletal muscle fibers by either L-carnitine or coenzyme Q10 against statins toxicity mediated by mitochondrial reactive oxygen generation. Front Physiol2013; 4: 103–103.
75.
BleskeBEWillisRAAnthonyM. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J2001; 142: E2–E2.
76.
FedackoJPellaDFedackovaP. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharmacol2013; 91: 165–170.
77.
BookstaverDABurkhalterNAHatzigeorgiouC. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol2012; 110: 526–529.
78.
ParkerBAGregorySMLorsonL. A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design. J Clin Lipidol2013; 7: 187–193.
79.
LarsenSStrideNHey-MogensenM. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol2013; 61: 44–53.
80.
SirventPMercierJVassortG. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun2005; 329: 1067–1075.
81.
GaltierFMuraTRaynaud de MauvergerE. Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers. Toxicol Appl Pharmacol2012; 263: 281–286.
82.
MikusCRBoyleLJBorengasserSJ. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol2013; 62: 709–714.
83.
SEARCH Collaborative Group. LinkEParishSArmitageJ. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med2008; 359: 789–799.
84.
DegorterMKTironaRGSchwarzUI. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet2013; 6: 400–408.
85.
NeuvonenPJNiemiMBackmanJT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther2006; 80: 565–581.
86.
MangraviteLMEngelhardtBEMedinaMW. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature2013; 502: 377–380.
87.
SacherJWeiglLWernerM. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther2005; 314: 1032–1041.
88.
JohnsonTEZhangXBleicherKB. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol2004; 200: 237–250.
89.
DirksAJJonesKM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol2006; 291: 1208–1212.
90.
BellDS. Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J2010; 103: 690–692.
91.
DuellPBConnorWE. Vitamin D deficiency is associated with myalgias in hyperlipidemic subjects taking statins. Circulation2008; 118: S470 (Abstract 3701)–S470 (Abstract 3701).
92.
LeePGreenfieldJRCampbellLV. Vitamin D insufficiency – a novel mechanism of statin-induced myalgia?Clin Endocrinol2009; 71: 154–156.
93.
AhmedWKhanNGlueckCJ. Low serum 25 (OH) vitamin D levels (<32 ng/ml) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res2009; 153: 11–16.
94.
GlueckCJAbuchaibeCWangP. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med Hypotheses2011; 77: 651–658.
95.
LindeRPengLDesaiM. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol2010; 2: 77–84.
96.
KurnikDHochmanIVesteman-LandesJ. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patient receiving statins. Clin Endocrinol2012; 77: 36–41.
97.
BackesJMBarnesBJRuisingerJF. A comparison of 25-hydroxyvitamin D serum levels among those with or without statin-associated myalgias. Atherosclerosis2011; 218: 247–249.
98.
BittnerVWengerNKWatersDD. Vitamin D levels are not related to myalgias in statin-treated patients with stable coronary disease. J Am Coll Cardiol2010; 55: 177–179.
99.
RiphagenIJvan der VeerEMuskietFA. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin2012; 7: 1247–1252.
100.
GuptaAThompsonPD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis2011; 215: 23–29.
101.
SinzingerHOguoghoA. Variable influence of statins on isoprostanes in hyperlipidemia. Adv Exp Med Biol2003; 525: 209–212.
102.
SinzingerHLupatelliGChehneF. Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J Clin Pharm Ther2001; 26: 303–310.
103.
ParkerBAThompsonPD. Effect of statins on skeletal muscle. Exerc Sport Sci Rev2012; 40: 188–194.
104.
JacobsonTA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc2008; 83: 687–700.
105.
ParkerBACapizziJAGrimaldiAS. Effect of statins on skeletal muscle function. Circulation2013; 127: 96–103.
106.
JoyTRHegeleRA. Narrative review: statin-related myopathy. Ann Intern Med2009; 150: 858–868.
107.
NeedhamMFabianVKnezevicW. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord2007; 17: 194–200.
PadalaSThompsonPD. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis2012; 222: 15–21.
110.
Del GrandeMChristopher-StineL. Expanding our understanding of statin myopathy: when is it autoimmune?Int J Clin Rheumatol2012; 7: 243–246.
111.
MammenALPakKWilliamsEK. Anti-HMG-CoA reductase antibodies are rare in statin users, including those with self-limited musculoskeletal side-effects. Arthritis Care Res (Hoboken)2012; 64: 269–272.
112.
WernerJLChristopher-StineLGhazarianSR. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum2012; 64: 4087–4093.
113.
LahayeCBeaufréreAMBoyerO. Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins. Joint Bone Spine2013; 13: S1297–319X.
114.
BrewsterLMCoronelCMSluiterW. Ethnic differences in tissue creatine kinase activity: an observational study. PLoS One2012; 7: e32471–e32471.
115.
KyriakidesTAngeliniCSchaeferJ. European Federation of Neurological Societies. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol2010; 17: 767–773.
116.
CannonCPBraunwaldEMcCabeCH. Pravastatin or Atorvastatin evaluation and infection therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med2004; 350: 1495–1504.
117.
SaguilA. Evaluation of the patient with muscle weakness. Am Fam Physician2005; 71: 1327–1336.
118.
Echaniz-LagunaAMohrMTranchantC. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med2010; 362: 564–565.
119.
1 MohauptMGKarasRHBabiychukEB. Association between statin-associated myopathy and skeletal muscle damage. CMAJ2009; 181: E11–E18.
120.
DraegerAMonastyrskayaKM MohauptM. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol2006; 210: 94–102.
121.
AsbachPPaetschIStawowyP. Statin-associated focal myositis. Int J Cardiol2009; 133: e33–e34.
122.
SidhuHSVenkatanarasimhaNBhatnagarG. Imaging features of therapeutic drug-induced musculoskeletal abnormalities. Radiographics2012; 32: 105–127.
123.
LupattelliGPalumboBSinzingerH. Statin induced myopathy does not show up in MIBI scintigraphy. Nucl Med Commun2001; 22: 575–578.
124.
KyriakidesTAngeliniCSchaeferJ. EFNS review on the role of muscle biopsy in the investigation of myalgia. Eur J Neurol2013; 20: 997–1005.
125.
HermannMBogsrudMPMoldenE. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther2006; 79: 532–539.
126.
FinegoldJAManistyCHGoldacreB. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol2014; 21: 464–474.
127.
JoyTRMonjedAZouGY. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med2014; 160: 301–310.
GlueckCJAregawiDAgloriaM. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther2006; 28: 933–942.
130.
HarrisLJThapaRBrownM. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. J Clin Lipidol2011; 5: 299–307.
131.
ZhangHPlutzkyJSkentzosS. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med2013; 158: 526–534.
132.
GudzuneKAMonroeAKSharmaR. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Ann Intern Med2014; 160: 468–476.
133.
MarcusFIBaumgartenAJFritzWL. Alternate-day dosing with statins. Am J Med2013; 126: 99–104.
134.
BackesJMVeneroCVGibsonCA. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother2008; 42: 341–346.
135.
RuisingerJFBackesJMGibsonCA. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol2009; 103: 393–394.
136.
GoldbergASDegorterMKBanMR. Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. Can J Cardiol2013; 29: 915–919.
137.
KennedySPBarnasGPSchmidtMJ. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol2011; 5: 308–315.
138.
AthyrosVGTziomalosKKakafikaAI. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol2008; 101: 483–485.
139.
BeckerDJGordonRYHalbertSC. Red yeast rice for dyslipidemia in statin-intolerant patients. Ann Intern Med2009; 150: 830–839.
140.
CiceroAFGDerosaGBoveM. Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. Curr Top Nutraceutical Res2009; 7: 121–126.
141.
RuscicaMGomaraschiMMombelliG. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidology2013; 8: 61–68.
142.
SikkaPKapoorSBindraVK. Statin intolerance: now a solved problem. J Postgrad Med2011; 57: 321–328.
143.
Derfler K, Steiner S, Sinzinger H. Lipoprotein-Apherese – Österreichischer Konsensus zu Indikation und Durchführung der Therapie. Wien Klin Wochenschr 2014 (in press).
144.
SacksFMPfefferMAMoyeLA. for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med1996; 335: 1001–1009.
145.
ShepherdJCobbeSMFordI. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med1995; 333: 1301–1307.
146.
PittBManciniGBEllisSG. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol1995; 26: 1133–1139.
147.
JukemaJWBruschkeAVvan BovenAJ. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation1995; 91: 2528–2540.
148.
Prevention of cadiovascular events and death with pravastatin in patients wirh coronary heart disease and a broad range of initial cholesterol levels. The long term intervention with pravastatin in ischaemic disease (LIPID) study group. N Engl J Med 1998; 339: 1349–1357.
149.
ShepherdJBlauwGJMurphyMB. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet2002; 360: 1623–1630.
150.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
151.
WenkeKMeiserBThieryJ. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation1997; 96: 1398–1402.
152.
HerdJABallantyneCMFarmerJA. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations: Lipoprotein and Coronary Atherosclerosis Study (LCAS). Am J Cardiol1997; 80: 278–286.
153.
RieggerGAbletshauserCLudwigM. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis1999; 144: 263–270.
154.
SerruysPWFoleyDPJacksonG. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur Heart J1999; 20: 58–69.
155.
HoldaasHJardineAGWheelerDC. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int2001; 60: 1990–1997.
156.
PittBWatersDBrownWV. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med1999; 341: 70–76.
157.
SchwartzGGOlssonAGEzekowitzMD. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA2001; 285: 1711–1718.
158.
AthyrosVGPapageorgiouAAMercourisBR. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention: the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin2002; 18: 220–228.
159.
PedersenTRFaergemanOKasteleinJJ. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA2005; 294: 2437–2445.
160.
NakamuraH1ArakawaKItakuraH. MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006; 368: 1155–1163.
161.
ColhounHM1BetteridgeDJDurringtonPN. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004; 364: 685–696.
162.
RidkerPMDanielsonEFonsecaFA. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008; 359: 2195–2207.
163.
GISSI-HF Investigators. TavazziLMaggioniAPMarchioliR. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet2008; 372: 1231–1239.
164.
WannerCKraneVMärzW. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med2005; 353: 238–248.
165.
FellströmBCJardineAGSchmiederRE. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med2009; 360: 1395–1407.
166.
BallantyneCMHouriJNotarbartoloA. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation2003; 107: 2409–2415.
167.
NissenSETuzcuEMSchoenhagenP. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA2004; 291: 1071–1080.
168.
DeedwaniaPStonePHBairey MerzCN. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation2007; 115: 700–707.
169.
AmarencoPBogousslavskyJCallahanA3rd. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med2006; 355: 549–559.
170.
ManciniGBBakerSBergeronJ. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol2011; 27: 635–662.
